|
HAMBURG, Germany, June 4, 2026 /PRNewswire/ -- ELEGOO, a rapidly developing brand in global smart manufacturing, is proud to announce an exciting partnership with the emoji® brand — bringing together two powerful symbols of creativity, fun, and self-expression.
The collaboration was brokered by emoji company's UK licensing agent, Big Picture Licensing, whose support helped bring together two globally recognized brands driven by innovation, creativity, and emotional connection.
ELEGOO has remained committed to making creation more accessible through intuitive 3D printing technology that transforms imagination into reality.
At the center of this collaboration is ELEGOO's flagship consumer printer, the Centauri Carbon 2 Combo — an iconic product designed to make high-quality 3D printing simple, intuitive, and enjoyable for everyone.
Introducing the first-ever emoji® brand themed 3D printer
ELEGOO × emoji® brand Centauri Carbon 2 Combo
This special edition features:
- A premium silver-white body design with exclusive emoji® brand designs and visual accents
- A customized UI interface featuring playful emoji® brand layouts for a more immersive experience
- The official emoji® brand 3D G-code model files, allowing users to instantly transform iconic digital expressions into physical creations
- A unique blend of lifestyle aesthetics, creativity, and cutting-edge maker technology
Together, ELEGOO and the emoji® brand are redefining creative expression — making it more emotional, personal, and tangible than ever before.
As the campaign slogan says:
"Your Vibe, Now in 3D."
Everything that feels like you, can now become something you can see, hold, create, and share.
When one emoji® brand icon meets another icon, the result is more than a product collaboration — it becomes a celebration of joy, individuality, and multicultural creativity.
Executive Quotes
"The emoji® brand has always represented emotions and connection, while ELEGOO stands for empowering creativity through technology," said Kevin Wang, VP of ELEGOO. "This partnership reflects our shared belief that self expression should be joyful, simple, and accessible to everyone. We're excited to bring that spirit into the world of 3D printing and help users turn feelings into something real."
Marco Hüsges, CEO and Founder of the emoji company, said: "We're incredibly excited to partner with ELEGOO on the very first collaboration between the emoji® brand and a 3D printing brand. Together, we're bringing digital self-expression into the physical world in a fun, creative, and completely new way.
This partnership highlights how 3D printing is evolving beyond traditional maker spaces and becoming part of everyday lifestyle technology — inspiring people to create, personalize, and express themselves like never before.
With the ELEGOO × emoji® Centauri Carbon 2 Combo, creativity becomes something you can truly see, hold, and share with the world."
Pricing and Availability
ELEGOO × emoji® Centauri Carbon 2 Combo is priced at $489 USD, €479 EUR, £415 GBP, $689 CAD, $1019 AUD and ￥89,999 JPY. Buyers can now place orders at ELEGOO official website where available shipping destinations include the United States, Great Britain, Canada, European Union, Australia and Japan.
About emoji® - The Iconic Brand
The emoji company is the owner of the emoji® brand, registered for a vast array of goods and services in over 150 countries. Its extensive rights portfolio encompasses over 1000 trademarks and over 25000 emoji® brand icons and designs. These are available for legal licensing and merchandising, including promotions, events, and marketing campaigns.
The emoji® brand, recognized globally, collaborates with over 1400 renowned license partners, including giants like Sony Pictures Animation, Pop Mart, BYD, New Era, Tonie´s, Trolli, PUMA, L´Oreal, and Burger King. Celebrated as the 3rd most influential brand behind Lego and Coca-Cola by a leading industry publication and with a retail revenue of more than 3 billion US$ in the past 6 years the emoji company stands at the #78 position among the Top 150 Global Licensors, cementing its status as a universal lifestyle brand of unprecedented influence.
Visit: www.emoji.com
About ELEGOO
Founded in 2015, ELEGOO is a rapidly developing brand in the global smart manufacturing industry, specializing in R&D, manufacturing, and sales of consumer-grade 3D printers, laser engravers, STEM kits, and other smart technology products. Located in Shenzhen, the Silicon Valley of China, the company has sold millions of products across more than 150 countries and regions. In 2025, the company's total sales revenue surpassed 300 million USD, with more than 1000 employees and over 430,000 square meters of office and manufacturing area. With a focus on programming and 3D printing technology, ELEGOO provides unique and smart creation spaces for diverse consumers to enhance personalized experiences.
Visit: www.elegoo.com
HAMBURG, Germany, June 4, 2026 /PRNewswire/ -- ELEGOO, a rapidly developing brand in global smart manufacturing, is proud to announce an exciting partnership with the emoji® brand — bringing together two powerful symbols of creativity, fun, and self-expression.
The collaboration was brokered by emoji company's UK licensing agent, Big Picture Licensing, whose support helped bring together two globally recognized brands driven by innovation, creativity, and emotional connection.
ELEGOO has remained committed to making creation more accessible through intuitive 3D printing technology that transforms imagination into reality.
At the center of this collaboration is ELEGOO's flagship consumer printer, the Centauri Carbon 2 Combo — an iconic product designed to make high-quality 3D printing simple, intuitive, and enjoyable for everyone.
Introducing the first-ever emoji® brand themed 3D printer
ELEGOO × emoji® brand Centauri Carbon 2 Combo
This special edition features:
- A premium silver-white body design with exclusive emoji® brand designs and visual accents
- A customized UI interface featuring playful emoji® brand layouts for a more immersive experience
- The official emoji® brand 3D G-code model files, allowing users to instantly transform iconic digital expressions into physical creations
- A unique blend of lifestyle aesthetics, creativity, and cutting-edge maker technology
Together, ELEGOO and the emoji® brand are redefining creative expression — making it more emotional, personal, and tangible than ever before.
As the campaign slogan says:
"Your Vibe, Now in 3D."
Everything that feels like you, can now become something you can see, hold, create, and share.
When one emoji® brand icon meets another icon, the result is more than a product collaboration — it becomes a celebration of joy, individuality, and multicultural creativity.
Executive Quotes
"The emoji® brand has always represented emotions and connection, while ELEGOO stands for empowering creativity through technology," said Kevin Wang, VP of ELEGOO. "This partnership reflects our shared belief that self expression should be joyful, simple, and accessible to everyone. We're excited to bring that spirit into the world of 3D printing and help users turn feelings into something real."
Marco Hüsges, CEO and Founder of the emoji company, said: "We're incredibly excited to partner with ELEGOO on the very first collaboration between the emoji® brand and a 3D printing brand. Together, we're bringing digital self-expression into the physical world in a fun, creative, and completely new way.
This partnership highlights how 3D printing is evolving beyond traditional maker spaces and becoming part of everyday lifestyle technology — inspiring people to create, personalize, and express themselves like never before.
With the ELEGOO × emoji® Centauri Carbon 2 Combo, creativity becomes something you can truly see, hold, and share with the world."
Pricing and Availability
ELEGOO × emoji® Centauri Carbon 2 Combo is priced at $489 USD, €479 EUR, £415 GBP, $689 CAD, $1019 AUD and ￥89,999 JPY. Buyers can now place orders at ELEGOO official website where available shipping destinations include the United States, Great Britain, Canada, European Union, Australia and Japan.
About emoji® - The Iconic Brand
The emoji company is the owner of the emoji® brand, registered for a vast array of goods and services in over 150 countries. Its extensive rights portfolio encompasses over 1000 trademarks and over 25000 emoji® brand icons and designs. These are available for legal licensing and merchandising, including promotions, events, and marketing campaigns.
The emoji® brand, recognized globally, collaborates with over 1400 renowned license partners, including giants like Sony Pictures Animation, Pop Mart, BYD, New Era, Tonie´s, Trolli, PUMA, L´Oreal, and Burger King. Celebrated as the 3rd most influential brand behind Lego and Coca-Cola by a leading industry publication and with a retail revenue of more than 3 billion US$ in the past 6 years the emoji company stands at the #78 position among the Top 150 Global Licensors, cementing its status as a universal lifestyle brand of unprecedented influence.
Visit: www.emoji.com
About ELEGOO
Founded in 2015, ELEGOO is a rapidly developing brand in the global smart manufacturing industry, specializing in R&D, manufacturing, and sales of consumer-grade 3D printers, laser engravers, STEM kits, and other smart technology products. Located in Shenzhen, the Silicon Valley of China, the company has sold millions of products across more than 150 countries and regions. In 2025, the company's total sales revenue surpassed 300 million USD, with more than 1000 employees and over 430,000 square meters of office and manufacturing area. With a focus on programming and 3D printing technology, ELEGOO provides unique and smart creation spaces for diverse consumers to enhance personalized experiences.
Visit: www.elegoo.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Creative Expression Takes Shape: ELEGOO Partners with emoji® - The Iconic Brand for a Special Co-Branded 3D Printer Centauri Carbon 2 Combo Edition
|
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
